This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
SALT LAKE CITY, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN, "Myriad" or the "Company")), a global leader in molecular diagnostics and precision...
Find out why these stocks held up well on a negative day for the markets.
Myriad Genetics, Inc. (NASDAQ:MYGN) reported adjusted earnings per share (EPS) of 41 cents in the fourth quarter of fiscal 2019, down 4.7% (5%) year over year. Adjusted EPS also...
Canopy Growth Corp (NYSE:CGC) is scheduled to report first-quarter fiscal 2020 results on Aug 14, after market close.In the fourth quarter of fiscal 2019, the company's loss per...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Sell||Sell||Strong Buy||Strong Buy||Strong Sell|
|Summary||Strong Sell||Neutral||Strong Buy||Strong Buy||Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1M||2||Aug 19|
|Upside Tasuki Gap Bullish||1H||4||Oct 11, 2019 11:00AM|
|Bullish Engulfing||1D||6||Oct 03, 2019|
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.